Osimertinib Re-challenge for EGFR-mutant NSCLC after  Osimertinib-induced Interstitial Lung Disease: A Case Report

Código QR

Osimertinib Re-challenge for EGFR-mutant NSCLC after  Osimertinib-induced Interstitial Lung Disease: A Case Report

Osimertinib-induced interstitial lung disease (ILD) is an uncommon, but fatal pulmonary toxicity in some patients. We report a case of a 64-year-old male with stage IV adeno-non-small cell lung cancer (NSCLC) harboring an exon 19 deletion in the epidermal growth factor receptor (EGFR) treated with o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Junjie GU, Fan BAI, Lan SONG, Yingyi WANG
Formato:	article
Lenguaje:	ZH
Publicado:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2021
Materias:	epidermal growth factor receptor interstitial lung disease lung neoplasms osimertinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/08ac61b7c38540368ddbabbcc8b08745
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
por: Svetlana V. Odintsova, et al.
Publicado: (2020)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
por: Akiko Takahashi, et al.
Publicado: (2018)

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
por: Santarpia M, et al.
Publicado: (2017)

Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis
por: Sergey V. Goryaynov
Publicado: (2021)

Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature
por: Klempner SJ, et al.
Publicado: (2017)

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
por: Zhu VW, et al.
Publicado: (2019)

High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
por: Zhang Ying, et al.
Publicado: (2021)

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report
por: Qian Shen, et al.
Publicado: (2021)

Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
por: Chin‐Chou Wang, et al.
Publicado: (2021)

A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
por: Igawa S, et al.
Publicado: (2021)

Assessing the Safety and Efficacy of Thoracoscopic Lung Biopsy in Patients with Interstitial Lung Disease
por: Mohamed Mustafa Elsheikh, et al.
Publicado: (2021)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen M, et al.
Publicado: (2018)

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation
por: Tian Tian, et al.
Publicado: (2021)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan J, et al.
Publicado: (2021)

Drug-Induced Interstitial Lung Disease after Anthracycline-Combined Chemotherapy for Breast Cancer: A Case Report and Literature Review
por: Hideko Hoshina, et al.
Publicado: (2021)

EGFR T790M: revealing the secrets of a gatekeeper
por: Ko B, et al.
Publicado: (2017)

Clopidogrel-Induced Interstitial Lung Disease: A Case Report
por: An J, et al.
Publicado: (2021)

Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
por: Yu D, et al.
Publicado: (2021)

Interstitial lung abnormalities – current knowledge and future directions
por: Gisli Thor Axelsson, et al.
Publicado: (2021)

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
por: Taichi Miyawaki, et al.
Publicado: (2021)

Interstitial Lung Disease in Connective Tissue Diseases: Survival Patterns in a Population-Based Cohort
por: Charlotte Hyldgaard, et al.
Publicado: (2021)

Skin Rash and Interstitial Pneumonia Can Be a Fatal Combination: A Rare Case of Anti-Melanoma Differentiation-Associated Gene 5 (MDA5)-Associated Interstitial Lung Disease
por: Giorgia Borio, et al.
Publicado: (2021)

An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece
por: Mountzios G, et al.
Publicado: (2021)

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
por: Maurício Fernando Silva Almeida Ribeiro, et al.
Publicado: (2021)

Comparison Study between Chest Ultrasonography and High Resolution CT in Diagnosis and Assessment of Interstitial Lung Diseases
por: Mohamed Gamal Mohamed Elmansy, et al.
Publicado: (2020)

Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients
por: Yaning Yang, et al.
Publicado: (2021)

Current Perspectives On Emerging Biomarkers For Rheumatoid Arthritis-Associated Interstitial Lung Disease
por: Amigues I, et al.
Publicado: (2019)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
por: Xiaoying Zhang
Publicado: (2021)

Progressive fibrosing interstitial lung disease: prevalence and clinical outcome
por: Byoung Soo Kwon, et al.
Publicado: (2021)

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
por: Yang W, et al.
Publicado: (2020)

Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives
por: Zulfikar S, et al.
Publicado: (2020)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
por: Brazel D, et al.
Publicado: (2021)

Variability in Global Prevalence of Interstitial Lung Disease
por: Bhavika Kaul, et al.
Publicado: (2021)

Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report
por: Masatomo Ueda, et al.
Publicado: (2021)

Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies
por: Abhinav K. Misra, et al.
Publicado: (2021)

Respiratory symptoms as initial manifestations of interstitial lung disease in clinically amyopathic juvenile dermatomyositis: a case report with literature review
por: Jingyi Xia, et al.
Publicado: (2021)

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
por: Lee CS, et al.
Publicado: (2020)

The relationship of SSRI and SNRI usage with interstitial lung disease and bronchiectasis in an elderly population: a case–control study
por: Rosenberg T, et al.
Publicado: (2017)

Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFRL858R/T790M mutation
por: Wang G, et al.
Publicado: (2019)

Hepatopulmonary syndrome complicated by interstitial pneumonia and obesity with normal contrast echocardiography
por: Akihito Okazaki, et al.
Publicado: (2021)